Alerta

BLOOD GLUCOSE DISEASE MANAGEMENT SYSTEM

Resumen de: US20260182931A1

0000 The disease management system can determine a measurement of one or more physiological parameters and can determine a disease event based on the one or more measurements. Furthermore, the disease management system can determine a pose of an individual using a pose sensor. Based on an identification of a disease event and a determination that the pose of the individual corresponds to a first pose, the disease management system can cause at least one of an audible, visual, or vibratory alarm. Based on an identification of a disease event and a determination that the pose of the individual does not correspond to the first pose, the disease management system can cause administration of a medication to the individual.

SYSTEMS AND METHODS FOR FOOD ANALYSIS, PERSONALIZED RECOMMENDATIONS, AND HEALTH MANAGEMENT

Resumen de: US20260182870A1

0000 Techniques disclosed herein relate to food analysis and glucose level management. In some examples, the techniques involve determining a consumption of a food item by a user, receiving data indicative of a glucose level of the user, determining an effect of the food item on the glucose level of the user based on a change of the glucose level of the user, and storing the effect of the food item on the glucose level of the user that includes data associated with one or more effects of the food item on the glucose level of the user.

ARTIFICIAL PANCREAS INTEGRATED CGM ARCHITECTURES AND DESIGNS

Resumen de: US20260183483A1

0000 A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.

DIABETIC KETOACIDOSIS RISK DETECTION AND MITIGATION

Resumen de: WO2026142762A1

In an embodiment, a system for mitigating diabetic ketoacidosis (DKA) risk for a patient in real-time includes a continuous glucose monitoring (CGM) system configured to generate one or more glucose measurements associated with a cunent glucose level of a patient over a period, one or more memories including executable instructions, and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive glucose measurements for the patient from the CGM system, receive insulin data for the patient, evaluate criteria associated with DKA using first information related to the glucose measurements and second information related to the insulin data, detect a risk of DKA for the patient responsive to a combination of the first information and the second information satisfying the criteria associated with DKA, and alert the patient based on the detected risk.

PERFORMANCE REPORTS ASSOCIATED WITH CONTINUOUS SENSOR DATA FROM MULTIPLE ANALYSIS TIME PERIODS

Resumen de: US20260188503A1

A method of providing performance reports to persons associated with the monitoring of an analyte level, such as blood glucose concentrations in a host, is provided. The performance reports can indicate a measure of an analyte variability of the host over a first analysis time period compared to a measure of analyte variability of the host over one or more other analysis time periods. The analyte level of the host can be received in each of a plurality of sensor readings from a continuous analyte sensor, such as multiple sensor readings per hour, so that the analyte variability that is used in determining the performance report of the host can be based on not just a few metered readings taken by the host, but a plurality of intermittent readings that are taken by a continuous analyte sensor, for example. Various types of performance reports can be generated, such as reports that comprise charts, graphs, tables, and/or other visual indicia of a host's performance during one analysis period versus another analysis period.

EXPANSION OF LYMPHOCYTES

Resumen de: US20260183397A1

0000 The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or suspected to contain lymphocytes; or (b) culturing lymphocytes, which lymphocytes are isolated from a tissue or blood sample from a subject; wherein the lymphocytes are expanded in a culture medium in which at least one of the following parameters is monitored and adjusted to a predefined value or range: pH, dissolved oxygen (DO) concentration, glucose concentration, lactate concentration and/or temperature; and wherein the method comprises a step of adjusting the culture volume to the expansion rate of the lymphocytes. Furthermore, the invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, optionally, and less than 10% are triple positive for CD45RA, CD57 and KLRG1.

INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND PROGRAM

Resumen de: WO2026141211A1

The present invention accurately predicts and notifies the degree of daily discomfort after food intake. The present invention comprises: an acquisition unit that acquires blood glucose-related data related to the blood glucose level of a subject; a prediction unit that, on the basis of the blood glucose-related data, predicts the degree of daily discomfort after a prescribed amount of time from food intake by the subject; and an output unit that outputs the result of prediction by the prediction unit.

INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING PROGRAM, AND INFORMATION PROCESSING METHOD

Resumen de: WO2026141270A1

Provided is an information processing system that provides users more useful information for improving blood sugar levels. The information processing system acquires meal information about meals consumed by a user, and outputs recommendation information on the basis of the meal information, user information, blood glucose level information, and behavioral information. Additionally, the information processing system outputs predicted blood glucose levels on the basis of meal information, user information, blood glucose level information, and behavioral information, the predicted blood glucose levels being for the case in which the user consumes a meal corresponding to the meal information. The information processing system also outputs blood glucose level prediction information on the basis of the recommended information. Moreover, the information processing system provides the user with blood glucose level prediction information based on meal information, recommendation information, and blood glucose level prediction information based on the recommendation information.

METHOD OF DETECTING AN ANOMALY OF A SIGNAL FROM A PHYSIOLOGICAL PARAMETER DETECTION APPARATUS, DEVICE AND MEDIUM

Resumen de: EP4769427A1

This application discloses a method and device for detecting an anomaly of a signal from a physiological parameter detection apparatus, particularly a continuous glucose monitor, CGM, comprising: acquiring a working parameter of the physiological parameter detection apparatus, wherein the working parameter comprises a working current; determining whether the signal from the physiological parameter detection apparatus is abnormal based on the working parameter: and outputting a detection result. Through the foregoing solution, an anomaly of a signal from the physiological parameter detection apparatus can be effectively detected, thereby ensuring signal accuracy.

INSULIN PUMP CONTROL METHOD AND APPARATUS, ARTIFICIAL PANCREATIC CLOSED-LOOP SYSTEM, AND STORAGE MEDIUM

Resumen de: EP4769422A1

An insulin pump control method and apparatus, an artificial pancreatic closed-loop system, and a storage medium are provided. The method includes: acquiring first monitoring data of a target object, obtaining an injection dosage of a first injection according to a target model and the first monitoring data, and injecting the target object based on the injection dosage of the first injection. The target model is adjusted based on total dosages corresponding to historical prediction failures.

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: EP4767938A2

0001 The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the applicator comprises a plunger body disposed at a first locating in an inner space of a main case and configured to downwardly move to a second location according to a manipulation of a pressure button. The pressure button is configured to be mode-changeable from a first mode, in which pressurizing movement by pressurizing manipulation is prevented, to a second mode, in which the pressurizing movement by the pressurizing manipulation is allowed.

METHOD FOR CONTROLLING BLOOD GLUCOSE AND ARTIFICIAL PANCREAS SYSTEM FOR CARRYING OUT THE METHOD

Resumen de: EP4767933A1

0001 A method for controlling glucose in a flexibly structured dual-hormone artificial pancreas that manages optional meal and/or exercise notifications using coordinated control actions, which comprises: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate intake as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) depending on the insulin bolus administered; defining a corrected incremental plasma glucose y(s), a corrected insulin infusion u(s), and a corrected carbohydrate d(s) intake; defining a virtual control action µ(s), divided into regulatory actions µr and counter-regulatory actions µcr and calculating control actions using a 2-DOF feedback controller with a nominal value pre-filter Fr(s).

ANALYTE SENSOR BASED ON BLOOD GLUCOSE MONITORING

Resumen de: EP4767931A1

The present application provides an analyte sensor based on blood glucose monitoring. The analyte sensor comprises a substrate, a working electrode, a reference electrode, a counter electrode, and a sensing layer; the sensing layer is provided on the working electrode; the working electrode, reference electrode, and counter electrode are provided at surfaces of the substrate, and the two electrodes from the working electrode; the working electrode, reference electrode, and counter electrode located at the same surface of the substrate are spatially separated by a channel. The analyte sensor can be implanted into a human body for monitoring, and has the characteristics of good flexibility, small size, low manufacturing cost, simple process flow, and long-term monitoring.

CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM FOR SAFE INFUSION

Resumen de: EP4769421A1

0001 The invention discloses a closed-loop artificial pancreas system for safe infusion, during a long period of real-time blood glucose value loss, the closed-loop artificial pancreas system can enter a learning mode or a safe mode. Based on historical blood glucose values and finger blood glucose values, it continues to calculate the required insulin infusion amount for the patient and infuses an appropriate amount of insulin to the patient. It will not infuse an inappropriate amount of insulin or even interrupt insulin infusion due to the lack of real-time blood glucose value, avoiding life-threatening situations for the patient and benefiting the patient's treatment.

MAGNETIC RESONANCE IMAGING OF SUGAR MOIETIES AND PH IN METABOLIC DYSFUNCTION

Resumen de: WO2026136617A1

Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen/glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.

APPLICATOR DEVICE FOR INSULIN PATCH PUMP WITH CANNULA DEPTH CONTROL

Resumen de: US20260174953A1

Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. According to one aspect, an applicator device includes a cannula and an insertion needle configured to insert the cannula into a body of a user. The applicator can include features that control the geometry of the skin during insertion of the cannula to provide a more reliable depth and insertion angle for the cannula.

ANALYTE PATTERN ANALYSIS

Resumen de: US20260174959A1

0000 A glucose data analysis system includes an on-body unit and a processor. The on-body unit is configured to measure glucose levels of a user. The processor is configured to receive therapy data of the user including glucose data monitored by the on-body unit, analyze daily glucose profiles of the glucose data over an analysis period by a machine learning model, group the daily glucose profiles into two or more patterns based on the analysis performed by the machine learning model, and output a report including identification of the two or more patterns associated with each daily glucose profile. Advantageously the system may identify and visualize patterns of glucose data, identify recurring patterns, identify correlations between patterns and external events (e.g., medication, meals, exercise, sleep, stress, etc.), reduce glycemic variability, streamline analysis with unsupervised machine learning (e.g., no training), and provide recommendations for user intervention or actions based on identified patterns.

CONTEXTUAL INPUT SYSTEM FOR AUTOMATED INSULIN DELIVERY

Resumen de: US20260174954A1

0000 An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

SYSTEMS AND METHODS FOR OPTIMIZING MEDICAMENT DOSING

Resumen de: US20260174961A1

A system for monitoring a patient includes one or more processors and a sensor device implemented in circuitry. The system is configured to measure, using the sensor device, a blood glucose status of the patient, and determine, using one or more processors, an initial insulin dose for the patient based on the blood glucose status of the patient. The system is further configured to optimize the initial insulin dose for the patient, based at least in part on a correction factor, to create an optimized insulin dose for the patient. The system is configured to facilitate therapy, using the one or more processors, based on the determined optimized insulin dose.

GLUCOSE ALERT PREDICTION HORIZON MODIFICATION

Resumen de: US20260174399A1

Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

Resumen de: US20260174960A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

MEDICINE INJECTION AND DISEASE MANAGEMENT SYSTEMS, DEVICES, AND METHODS

Resumen de: US20260174969A1

0000 Diabetes management systems may include a glucose monitoring device adapted to transmit glucose data and at least one accessory in communication with the glucose monitoring device and adapted to provide at least one alarm or alert based on the glucose data.

CELL CULTURED BERRIES AND PRODUCTS DERIVED THEREFROM

Resumen de: AU2024395220A1

The present invention provides culture-derived berry cells compositions which have a high phenolic acid and low anthocyanins in their polyphenolic fraction, and are high in protein, low in sugar, and have a high antioxidation potential.

METHODS OF MAKING STEM CELL-DERIVED ISLET-LIKE CELLS, AS WELL AS POPULATIONS AND COMPOSITIONS INCLUDING THE SAME

Resumen de: AU2024391032A1

Methods are disclosed for making a stem cell-derived islet-like cell (SC-IC) population, where such methods include culturing precursor cells such as pancreatic progenitor cells, pancreatic endocrine precursor cells or immature SC-ICs one or more differentiation mediums that promote the differentiation of the precursor cells to more differentiated cells to obtain an SC-IC population that includes mature pancreatic-beta-like cells. Also disclosed are cell-differentiating compositions useful in performing the methods and SC-IC populations obtained by performing the methods. Also disclosed are compositions and implantable devices comprising the SC-IC populations, which are useful thereof for treatment of metabolic disorders such as diabetes mellitus (diabetes).

Insulin needle tip protection mechanism and insulin injection device

Nº publicación: US20260174975A1 25/06/2026

Solicitante:

NINGBO MEDSUN MEDICAL CO LTD [CN]
NINGBO MEDSUN MEDICAL CO., LTD.

Resumen de: US20260174975A1

0000 This invention discloses a protective mechanism for insulin needles and an insulin injection device. Through the cooperation of a U-shaped reciprocating slot and a flexible wall, it is possible to automatically retract the needle tip after injection, and prevent it from being pushed out again, thus achieving the purpose of needle tip protection and avoiding reuse.